Literature DB >> 12063079

Effects of dronedarone and amiodarone on plasma thyroid hormones and on the basal and postischemic performance of the isolated rat heart.

Constantinos Pantos1, Iordanis Mourouzis, Martine Delbruyère, Vassiliki Malliopoulou, Stylianos Tzeis, Demosthenis D Cokkinos, Nikos Nikitas, Hariclia Carageorgiou, Dennis Varonos, Dennis Cokkinos, Dino Nisato.   

Abstract

The present study investigated the effects of dronedarone and amiodarone on plasma thyroid hormones and the possible consequences on the response of the heart to ischemia. Amiodarone (30 mg/kg/day per os) or dronedarone (30 mg/kg/day per os) were administered for 2 weeks in normal and thyroxine-treated animals (25 microg/100 g body weight od sc, for 2 weeks), while animals without amiodarone and dronedarone served as controls. Isolated rat hearts were perfused in a Langendorff mode and subjected to 20 and 30 min of zero-flow global ischemia followed by 45 min of reperfusion. Functional changes were assessed by measuring left ventricular developed pressure (LVDP) under resting conditions and in response to ischemia-reperfusion, LVDP%, as well as the severity of ischemic contracture. Amiodarone resulted in increased T4, T4/T3 and rT3, whereas dronedarone did not alter the thyroid hormone profile in normal animals. In thyroxine-treated animals, amiodarone increased T4/T3 ratio but T4, T3 and rT3 levels were not altered. Basal functional parameters and ischemic contracture did not change by amiodarone and/or dronedarone neither in normal nor in thyroxine-treated hearts. In normal hearts, postischemic functional recovery, LVDP%, was not altered by amiodarone or dronedarone administration. LVDP% was statistically higher in thyroxine-treated hearts than in normal and this beneficial effect was not abolished by amiodarone or dronedarone treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12063079     DOI: 10.1016/s0014-2999(02)01624-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Thyroid hormone: a resurgent treatment for an emergent concern.

Authors:  Mason T Breitzig; Matthew D Alleyn; Richard F Lockey; Narasaiah Kolliputi
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-09-27       Impact factor: 5.464

2.  Acute T3 treatment protects the heart against ischemia-reperfusion injury via TRα1 receptor.

Authors:  Constantinos Pantos; Iordanis Mourouzis; Theodosios Saranteas; Vassiliki Brozou; Georgios Galanopoulos; Georgia Kostopanagiotou; Dennis V Cokkinos
Journal:  Mol Cell Biochem       Date:  2011-03-26       Impact factor: 3.396

Review 3.  [Modern pharmacotherapy of supraventricular and ventricular cardiac arrhythmia. An update for conventional therapy].

Authors:  D Steven; B Lutomsky; T Rostock; S Willems
Journal:  Internist (Berl)       Date:  2006-10       Impact factor: 0.743

Review 4.  Dronedarone.

Authors:  Sheridan M Hoy; Susan J Keam
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

Review 5.  The emerging role of TRα1 in cardiac repair: potential therapeutic implications.

Authors:  Constantinos Pantos; Iordanis Mourouzis
Journal:  Oxid Med Cell Longev       Date:  2014-02-09       Impact factor: 6.543

6.  Effects of ischemic postconditioning on the hemodynamic parameters and heart nitric oxide levels of hypothyroid rats.

Authors:  Sajad Jeddi; Jalal Zaman; Asghar Ghasemi
Journal:  Arq Bras Cardiol       Date:  2014-11-28       Impact factor: 2.000

7.  Comparative effects of amiodarone and dronedarone treatments on cardiac function in a rabbit model.

Authors:  Worakan Boonhoh; Anusak Kijtawornrat; Suwanakiet Sawangkoon
Journal:  Vet World       Date:  2019-02-28

8.  Dronedarone produces early regression of myocardial remodelling in structural heart disease.

Authors:  Begoña Quintana-Villamandos; Jose Juan Gomez de Diego; María Jesús Delgado-Martos; David Muñoz-Valverde; María Luisa Soto-Montenegro; Manuel Desco; Emilio Delgado-Baeza
Journal:  PLoS One       Date:  2017-11-21       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.